All lobbying filings

ORCHARD THERAPEUTICS NORTH AMERICA

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Health

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $190,000.00 expenses · posted Jul 17, 2026

Official filing document

Bills named in this filing 2

S 1637
MVP Act
HR 7871
MVP Act

Lobbying activity 2

Health Issues

FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD)

Medicare/Medicaid

S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.